A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs LY 2510924 (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 15 Mar 2017 Results of exploratory analysis published in the Investigational New Drugs
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 03 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.